Search
Close this search box.

Month: May 2025

Celebrating One year of the Brief Conversations Toolkit: Empowering Canadian youth to quit vaping

This year marks the first anniversary of the Brief Conversations Toolkit, a valuable resource developed in collaboration with Ontario Public Health Units and the Lung Health Foundation. Designed to address the youth vaping epidemic in Canada, the toolkit aids to support individuals who work with or care about youth – such as educators, school staff, coaches, youth workers, and parents. The toolkit strives to make room for engagement in meaningful, impactful conversations about quitting vaping while breaking things down into bite-sized lessons.

The Benefits of Having a Will—and How You Can Leave a Lasting Legacy

Protect your loved ones, gain peace of mind, and support a healthier future for Canadians living with lung disease.

Having a Will is about more than distributing assets—it’s about making a lasting impact. During Leave a Legacy Month, we invite you to think beyond today and consider how your legacy can help shape a healthier tomorrow for all Canadians.

Say “Yes” Again: How You Can Help Canadians Living with Asthma Enjoy More of Life

Asthma doesn’t just affect the lungs—it affects moments, memories, and confidence.

For many of the 4.6 million Canadians living with asthma, it’s not just about managing symptoms. It’s about navigating daily life with caution. It’s about hesitating before saying yes to that hike, yes to that dance, or even yes to walking to school on a chilly morning.

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the cancer from coming back, if certain conditions are met.